nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—POU2F2—Ectoderm Differentiation—EDA—melanoma	0.0602	0.0918	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—POU3F2—melanoma	0.0414	0.063	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—PAX3—melanoma	0.033	0.0503	CbGpPWpGaD
Dolutegravir—Rash generalised—Vemurafenib—melanoma	0.0317	0.0922	CcSEcCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—FASN—melanoma	0.0304	0.0464	CbGpPWpGaD
Dolutegravir—UGT1A1—Glucuronidation—UGT2B10—melanoma	0.0283	0.0431	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—ETS1—melanoma	0.0268	0.0409	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—MAP2—melanoma	0.0238	0.0362	CbGpPWpGaD
Dolutegravir—UGT1A1—Glucuronidation—UGT2B10—melanoma	0.0229	0.0349	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—VDR—melanoma	0.0228	0.0347	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—SYK—melanoma	0.0205	0.0312	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TP73—melanoma	0.0202	0.0308	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—HDAC6—melanoma	0.0178	0.0271	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—ATM—melanoma	0.0176	0.0267	CbGpPWpGaD
Dolutegravir—Opportunistic infection—Temozolomide—melanoma	0.0171	0.0497	CcSEcCtD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—melanoma	0.0168	0.0256	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—RAC1—melanoma	0.0147	0.0223	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—PAX6—melanoma	0.014	0.0213	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—melanoma	0.0136	0.0207	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—melanoma	0.0134	0.0204	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—MDM2—melanoma	0.013	0.0197	CbGpPWpGaD
Dolutegravir—Rash maculo-papular—Vemurafenib—melanoma	0.0122	0.0356	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—MAP2K1—melanoma	0.011	0.0167	CbGpPWpGaD
Dolutegravir—Rash generalised—Docetaxel—melanoma	0.0108	0.0313	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—ARNT—melanoma	0.0106	0.0161	CbGpPWpGaD
Dolutegravir—Prurigo—Docetaxel—melanoma	0.00991	0.0288	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—UGT2B10—melanoma	0.00865	0.0132	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1B1—melanoma	0.00863	0.0131	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL10—melanoma	0.00849	0.0129	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC39A12—melanoma	0.00832	0.0127	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—melanoma	0.0082	0.0125	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—NFKB1—melanoma	0.00817	0.0124	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—melanoma	0.00715	0.0109	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—melanoma	0.00701	0.0107	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK1—melanoma	0.00667	0.0102	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—APC—melanoma	0.00627	0.00954	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—melanoma	0.00579	0.00882	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—melanoma	0.00536	0.00816	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—UGT2B10—melanoma	0.00506	0.00771	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00497	0.0145	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Docetaxel—melanoma	0.00484	0.0141	CcSEcCtD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—melanoma	0.00473	0.0072	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNB1—melanoma	0.00472	0.00719	CbGpPWpGaD
Dolutegravir—Inflammation—Docetaxel—melanoma	0.00472	0.0137	CcSEcCtD
Dolutegravir—Nervous system disorder—Vemurafenib—melanoma	0.00471	0.0137	CcSEcCtD
Dolutegravir—Skin disorder—Vemurafenib—melanoma	0.00466	0.0136	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—melanoma	0.00464	0.00707	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	0.00449	0.00683	CbGpPWpGaD
Dolutegravir—Neutropenia—Dactinomycin—melanoma	0.00446	0.013	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CASP3—melanoma	0.00444	0.00677	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Temozolomide—melanoma	0.0044	0.0128	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.00428	0.00652	CbGpPWpGaD
Dolutegravir—Neutropenia—Carmustine—melanoma	0.00418	0.0122	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—NFKB1—melanoma	0.00415	0.00633	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Vemurafenib—melanoma	0.00415	0.0121	CcSEcCtD
Dolutegravir—Fatigue—Vemurafenib—melanoma	0.00414	0.0121	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—melanoma	0.00408	0.00621	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—EPHA2—melanoma	0.00406	0.00619	CbGpPWpGaD
Dolutegravir—Neutropenia—Temozolomide—melanoma	0.00404	0.0117	CcSEcCtD
Dolutegravir—Hyperglycaemia—Carmustine—melanoma	0.00403	0.0117	CcSEcCtD
Dolutegravir—Renal failure—Carmustine—melanoma	0.00391	0.0114	CcSEcCtD
Dolutegravir—Hyperglycaemia—Temozolomide—melanoma	0.00389	0.0113	CcSEcCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—melanoma	0.00383	0.00583	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC6A11—melanoma	0.00382	0.00582	CbGpPWpGaD
Dolutegravir—Hepatitis—Dactinomycin—melanoma	0.00382	0.0111	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—melanoma	0.00377	0.00574	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Temozolomide—melanoma	0.00364	0.0106	CcSEcCtD
Dolutegravir—Hypersensitivity—Vemurafenib—melanoma	0.00354	0.0103	CcSEcCtD
Dolutegravir—Renal impairment—Docetaxel—melanoma	0.00349	0.0102	CcSEcCtD
Dolutegravir—Hepatitis—Temozolomide—melanoma	0.00345	0.0101	CcSEcCtD
Dolutegravir—Asthenia—Vemurafenib—melanoma	0.00345	0.01	CcSEcCtD
Dolutegravir—Urinary tract disorder—Temozolomide—melanoma	0.00341	0.00993	CcSEcCtD
Dolutegravir—Pruritus—Vemurafenib—melanoma	0.0034	0.00989	CcSEcCtD
Dolutegravir—Urethral disorder—Temozolomide—melanoma	0.00339	0.00986	CcSEcCtD
Dolutegravir—Diarrhoea—Vemurafenib—melanoma	0.00329	0.00956	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TNF—melanoma	0.00323	0.00492	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1B10—melanoma	0.00321	0.0049	CbGpPWpGaD
Dolutegravir—Dizziness—Vemurafenib—melanoma	0.00318	0.00924	CcSEcCtD
Dolutegravir—Mental disorder—Carmustine—melanoma	0.00313	0.00912	CcSEcCtD
Dolutegravir—Immune system disorder—Temozolomide—melanoma	0.00312	0.00908	CcSEcCtD
Dolutegravir—Vomiting—Vemurafenib—melanoma	0.00305	0.00889	CcSEcCtD
Dolutegravir—Abdominal pain upper—Docetaxel—melanoma	0.00303	0.00883	CcSEcCtD
Dolutegravir—Rash—Vemurafenib—melanoma	0.00303	0.00881	CcSEcCtD
Dolutegravir—Mental disorder—Temozolomide—melanoma	0.00303	0.00881	CcSEcCtD
Dolutegravir—Dermatitis—Vemurafenib—melanoma	0.00303	0.00881	CcSEcCtD
Dolutegravir—Headache—Vemurafenib—melanoma	0.00301	0.00876	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Docetaxel—melanoma	0.00293	0.00853	CcSEcCtD
Dolutegravir—Nausea—Vemurafenib—melanoma	0.00285	0.0083	CcSEcCtD
Dolutegravir—Vertigo—Temozolomide—melanoma	0.0027	0.00786	CcSEcCtD
Dolutegravir—Neutropenia—Docetaxel—melanoma	0.00268	0.00781	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—melanoma	0.00261	0.00397	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00254	0.0074	CcSEcCtD
Dolutegravir—Renal failure—Docetaxel—melanoma	0.00252	0.00732	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Docetaxel—melanoma	0.00242	0.00705	CcSEcCtD
Dolutegravir—Nervous system disorder—Temozolomide—melanoma	0.00241	0.00701	CcSEcCtD
Dolutegravir—Skin disorder—Temozolomide—melanoma	0.00238	0.00694	CcSEcCtD
Dolutegravir—Fatigue—Dactinomycin—melanoma	0.00234	0.00681	CcSEcCtD
Dolutegravir—Hepatitis—Docetaxel—melanoma	0.0023	0.00669	CcSEcCtD
Dolutegravir—Insomnia—Carmustine—melanoma	0.0023	0.00669	CcSEcCtD
Dolutegravir—Urinary tract disorder—Docetaxel—melanoma	0.00227	0.0066	CcSEcCtD
Dolutegravir—Urethral disorder—Docetaxel—melanoma	0.00225	0.00656	CcSEcCtD
Dolutegravir—Insomnia—Temozolomide—melanoma	0.00222	0.00646	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Dactinomycin—melanoma	0.00222	0.00646	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Carmustine—melanoma	0.00219	0.00638	CcSEcCtD
Dolutegravir—Abdominal pain—Dactinomycin—melanoma	0.00215	0.00624	CcSEcCtD
Dolutegravir—Hypersensitivity—Bleomycin—melanoma	0.00214	0.00624	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Temozolomide—melanoma	0.00212	0.00617	CcSEcCtD
Dolutegravir—Fatigue—Temozolomide—melanoma	0.00212	0.00616	CcSEcCtD
Dolutegravir—Asthenia—Bleomycin—melanoma	0.00209	0.00608	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Carmustine—melanoma	0.00208	0.00605	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—melanoma	0.00207	0.00604	CcSEcCtD
Dolutegravir—Pruritus—Bleomycin—melanoma	0.00206	0.00599	CcSEcCtD
Dolutegravir—Mental disorder—Docetaxel—melanoma	0.00201	0.00586	CcSEcCtD
Dolutegravir—Abdominal pain—Carmustine—melanoma	0.00201	0.00584	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Temozolomide—melanoma	0.00201	0.00584	CcSEcCtD
Dolutegravir—Hypersensitivity—Dactinomycin—melanoma	0.002	0.00582	CcSEcCtD
Dolutegravir—Asthenia—Dactinomycin—melanoma	0.00195	0.00567	CcSEcCtD
Dolutegravir—Abdominal pain—Temozolomide—melanoma	0.00194	0.00565	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—melanoma	0.00192	0.00292	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Carmustine—melanoma	0.00187	0.00545	CcSEcCtD
Dolutegravir—Diarrhoea—Dactinomycin—melanoma	0.00186	0.0054	CcSEcCtD
Dolutegravir—Vomiting—Bleomycin—melanoma	0.00185	0.00538	CcSEcCtD
Dolutegravir—Rash—Bleomycin—melanoma	0.00183	0.00534	CcSEcCtD
Dolutegravir—Dermatitis—Bleomycin—melanoma	0.00183	0.00534	CcSEcCtD
Dolutegravir—Asthenia—Carmustine—melanoma	0.00182	0.0053	CcSEcCtD
Dolutegravir—Hypersensitivity—Temozolomide—melanoma	0.00181	0.00526	CcSEcCtD
Dolutegravir—Asthenia—Temozolomide—melanoma	0.00176	0.00513	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC5A5—melanoma	0.00175	0.00266	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—melanoma	0.00174	0.00265	CbGpPWpGaD
Dolutegravir—Diarrhoea—Carmustine—melanoma	0.00174	0.00506	CcSEcCtD
Dolutegravir—Pruritus—Temozolomide—melanoma	0.00174	0.00505	CcSEcCtD
Dolutegravir—Nausea—Bleomycin—melanoma	0.00173	0.00503	CcSEcCtD
Dolutegravir—Vomiting—Dactinomycin—melanoma	0.00173	0.00502	CcSEcCtD
Dolutegravir—Rash—Dactinomycin—melanoma	0.00171	0.00498	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—melanoma	0.0017	0.00259	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00169	0.00492	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP17A1—melanoma	0.00169	0.00257	CbGpPWpGaD
Dolutegravir—Dizziness—Carmustine—melanoma	0.00168	0.00489	CcSEcCtD
Dolutegravir—Diarrhoea—Temozolomide—melanoma	0.00168	0.00489	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP17A1—melanoma	0.00166	0.00253	CbGpPWpGaD
Dolutegravir—Dizziness—Temozolomide—melanoma	0.00162	0.00472	CcSEcCtD
Dolutegravir—Vomiting—Carmustine—melanoma	0.00161	0.0047	CcSEcCtD
Dolutegravir—Nausea—Dactinomycin—melanoma	0.00161	0.00469	CcSEcCtD
Dolutegravir—Rash—Carmustine—melanoma	0.0016	0.00466	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—melanoma	0.0016	0.00466	CcSEcCtD
Dolutegravir—Dermatitis—Carmustine—melanoma	0.0016	0.00466	CcSEcCtD
Dolutegravir—Headache—Carmustine—melanoma	0.00159	0.00463	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—melanoma	0.00159	0.00461	CcSEcCtD
Dolutegravir—Vomiting—Temozolomide—melanoma	0.00156	0.00454	CcSEcCtD
Dolutegravir—Rash—Temozolomide—melanoma	0.00155	0.0045	CcSEcCtD
Dolutegravir—Dermatitis—Temozolomide—melanoma	0.00155	0.0045	CcSEcCtD
Dolutegravir—Headache—Temozolomide—melanoma	0.00154	0.00448	CcSEcCtD
Dolutegravir—Nausea—Carmustine—melanoma	0.00151	0.00439	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—melanoma	0.00148	0.0043	CcSEcCtD
Dolutegravir—Nausea—Temozolomide—melanoma	0.00146	0.00424	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1B1—melanoma	0.00142	0.00216	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Docetaxel—melanoma	0.00141	0.0041	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—melanoma	0.00141	0.0041	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1B1—melanoma	0.0014	0.00213	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Docetaxel—melanoma	0.00133	0.00388	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—melanoma	0.0013	0.00198	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—HGF—melanoma	0.00129	0.00197	CbGpPWpGaD
Dolutegravir—Abdominal pain—Docetaxel—melanoma	0.00129	0.00376	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—melanoma	0.00124	0.00189	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Docetaxel—melanoma	0.0012	0.0035	CcSEcCtD
Dolutegravir—Asthenia—Docetaxel—melanoma	0.00117	0.00341	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—melanoma	0.00115	0.00336	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—melanoma	0.00112	0.00325	CcSEcCtD
Dolutegravir—Dizziness—Docetaxel—melanoma	0.00108	0.00314	CcSEcCtD
Dolutegravir—Vomiting—Docetaxel—melanoma	0.00104	0.00302	CcSEcCtD
Dolutegravir—Rash—Docetaxel—melanoma	0.00103	0.003	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—melanoma	0.00103	0.00299	CcSEcCtD
Dolutegravir—Headache—Docetaxel—melanoma	0.00102	0.00298	CcSEcCtD
Dolutegravir—Nausea—Docetaxel—melanoma	0.000969	0.00282	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ACER3—melanoma	0.000946	0.00144	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—UGT2B10—melanoma	0.000865	0.00132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HS3ST5—melanoma	0.000804	0.00123	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PLCB4—melanoma	0.000609	0.000928	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIP4K2A—melanoma	0.000573	0.000873	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC6A11—melanoma	0.000573	0.000873	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTAP—melanoma	0.000557	0.000849	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—LUM—melanoma	0.000497	0.000757	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PHGDH—melanoma	0.000497	0.000757	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HPSE—melanoma	0.000487	0.000742	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CUBN—melanoma	0.000478	0.000729	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SDHD—melanoma	0.000462	0.000704	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CSPG4—melanoma	0.000462	0.000704	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—BSG—melanoma	0.000462	0.000704	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GPAM—melanoma	0.000447	0.000681	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PLA2G6—melanoma	0.00038	0.000579	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—VCAN—melanoma	0.000342	0.00052	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP17A1—melanoma	0.000288	0.000439	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GNA11—melanoma	0.000272	0.000415	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FASN—melanoma	0.000266	0.000406	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC5A5—melanoma	0.000262	0.000399	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GNAQ—melanoma	0.000253	0.000386	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CD44—melanoma	0.000253	0.000386	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1B1—melanoma	0.000243	0.00037	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCB1—melanoma	0.0002	0.000304	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PRKCA—melanoma	0.000184	0.00028	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ERCC2—melanoma	0.000182	0.000278	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CG—melanoma	0.000144	0.000219	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPARG—melanoma	0.000139	0.000212	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CD—melanoma	0.000127	0.000193	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALB—melanoma	0.000125	0.00019	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CB—melanoma	0.00011	0.000168	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—melanoma	0.000109	0.000167	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—melanoma	9.54e-05	0.000145	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—melanoma	6.73e-05	0.000102	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—melanoma	5.5e-05	8.37e-05	CbGpPWpGaD
